Evidence map›Paper›PMID 26792470›Full record

Observational studyThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2016

Undertreated HIV and drug-resistant tuberculosis at a referral hospital in Irkutsk, Siberia.

S K Heysell, O B Ogarkov, S Zhdanova, E Zorkaltseva, S Shugaeva, J Gratz, S Vitko, E D Savilov, M E Koshcheyev, E R Houpt

Abstract readObservational Study
In one paragraph

Observational study in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018
    Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

S K HeysellDivision of Infectious Diseases and International Health, University of Virginia, Charlottesville, Virginia, USA.
O B OgarkovScientific Centre for Family Health and Human Reproduction Problems, Irkutsk, Russian Federation; Regional TB Prevention Dispensary, Irkutsk, Russian Federation.
S ZhdanovaScientific Centre for Family Health and Human Reproduction Problems, Irkutsk, Russian Federation.
E ZorkaltsevaRegional TB Prevention Dispensary, Irkutsk, Russian Federation; State Medical Continuing Education Academy, Irkutsk, Russian Federation.
S ShugaevaRegional TB Prevention Dispensary, Irkutsk, Russian Federation.
J GratzDivision of Infectious Diseases and International Health, University of Virginia, Charlottesville, Virginia, USA.
S VitkoDivision of Infectious Diseases and International Health, University of Virginia, Charlottesville, Virginia, USA.
E D SavilovScientific Centre for Family Health and Human Reproduction Problems, Irkutsk, Russian Federation; State Medical Continuing Education Academy, Irkutsk, Russian Federation.
M E KoshcheyevRegional TB Prevention Dispensary, Irkutsk, Russian Federation.
E R Houpt<sup>*</sup>Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, Virginia, USA.

Funding

Clinical Impact of Anti-TB Drug Levels and M. Tuberculosis SusceptibilityK23AI099019 · NIAID · UNIVERSITY OF VIRGINIA · PI HEYSELL, SCOTT K · 2012 to 2016
$649k
Genotyping and Pharmacokinetics in the HIV/MDR-TB epidemic of Eastern SiberiaR21AI108521 · NIAID · UNIVERSITY OF VIRGINIA · PI HOUPT, ERIC R · 2014 to 2015
$379k
NIAID NIH HHS K23 AI099019NIAID NIH HHS R21 AI108521
6 · The paper itself

Abstract

settingA referral hospital for tuberculosis (TB) in Irkutsk, the Russian Federation.

objectiveTo describe disease characteristics, treatment and hospital outcomes of TB-HIV (human immunodeficiency virus).

designObservational cohort of HIV-infected patients admitted for anti-tuberculosis treatment over 6 months.

resultsA total of 98 patients were enrolled with a median CD4 count of 147 cells/mm(3) and viral load of 205 943 copies/ml. Among patients with drug susceptibility testing (DST) results, 29 (64%) were multidrug-resistant (MDR), including 12 without previous anti-tuberculosis treatment. Nineteen patients were on antiretroviral therapy (ART) at admission, and 10 (13% ART-naïve) were started during hospitalization. Barriers to timely ART initiation included death, in-patient treatment interruption, and patient refusal. Of 96 evaluable patients, 21 (22%) died, 14 (15%) interrupted treatment, and 10 (10%) showed no microbiological or radiographic improvement. Patients with a cavitary chest X-ray (aOR 7.4, 95%CI 2.3-23.7, P = 0.001) or central nervous system disease (aOR 6.5, 95%CI 1.2-36.1, P = 0.03) were more likely to have one of these poor outcomes.

conclusionHigh rates of MDR-TB, treatment interruption and death were found in an HIV-infected population hospitalized in Irkutsk. There are opportunities for integration of HIV and TB services to overcome barriers to timely ART initiation, increase the use of anti-tuberculosis regimens informed by second-line DST, and strengthen out-patient diagnosis and treatment networks.

Indexed as

CoinfectionDrug Resistance, Multiple, BacterialHospitalizationReferral and ConsultationAdultAnti-HIV AgentsAntitubercular AgentsChi-Square DistributionDrug Therapy, CombinationFemaleHIV InfectionsHospital MortalityHumansLogistic ModelsMaleMicrobial Sensitivity TestsAnti-HIV AgentsAntitubercular Agents

Identifiers

PMID26792470
PMCPMC4863947

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.